Syndax Pharmaceuticals (SNDX) Net Income towards Common Stockholders Growth (3y) (2018 - 2026)

Syndax Pharmaceuticals (SNDX) Net Income towards Common Stockholders Growth (3y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 84.25%
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -10.84%
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 26.38%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 34.98%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -46.86%
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 13.80%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Syndax Pharmaceuticals 1.69 Bn 1.34 Bn 53.02 Mn 9.24%

Historic Data

Download Data
DateValue
Mar 31, 2026 9.24%
Dec 31, 2025 -14.20%
Sep 30, 2025 -14.10%
Jun 30, 2025 -19.09%
Mar 31, 2025 -27.11%
Dec 31, 2024 -43.09%
Sep 30, 2024 -59.87%
Jun 30, 2024 -43.80%
Mar 31, 2024 -37.77%
Dec 31, 2023 -52.58%
Sep 30, 2023 -35.99%
Jun 30, 2023 -37.78%
Mar 31, 2023 -39.13%
Dec 31, 2022 -40.87%
Sep 30, 2022 -40.15%
Jun 30, 2022 -36.16%
Mar 31, 2022 -37.45%
Dec 31, 2021 92.15%
Sep 30, 2021 -5.88%
Jun 30, 2021 -7.32%